Key points from article :
Human Longevity, the company that combines genomics and health data to try to extend healthy lifespan, has launched a new company called Human Life Foundation Models (HLFM). HLFM will build large AI "foundation models" for longevity science and has signed a multi-year, multi-million-dollar collaboration with AI drug discovery company Insilico Medicine.
The new company will draw on Human Longevity's decade-long collection of genomic, imaging and clinical data, while Insilico contributes its AI architecture and model-training expertise. The aim is to build models that can explain the biological mechanisms of ageing, predict disease risk and support earlier, more preventive care. Wei-Wu He, Executive Chairman of Human Longevity, said the goal is a model "that can help predict complex disease decades before it occurs and guide interventions to extend healthy lifespan."
The deal adds to a busy period for Insilico, which raised $293 million in a Hong Kong IPO at the end of 2025 and expanded its partnership with Eli Lilly in March in a deal worth up to $2.75 billion.
The financial terms of the HLFM collaboration have not been disclosed, and details of the new company's funding and ownership have not been made public. The plans for the models come from the companies' own announcement and have yet to be tested in practice.
